Anixa Biosciences is trading 6.5% down today at $3.46 as the stock undergoes consolidation following a significant rally last week.
- The recent surge was fueled by a Zacks Research upgrade to Strong Buy and a price target increase to $8.50, triggered by a narrower-than-expected quarterly loss.
- With no fresh company-specific news today and the broader biotech sector remaining firm, the move is viewed as profit-taking following recent analyst-driven strength rather than a fundamental setback.